M. Et and M. , 67 13.2.1 POPULATION, p.68

U. Pape, A. Perren, B. Niederle, D. Gross, T. Gress et al., ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas, Neuroendocrinology, vol.90, issue.2, pp.135-56, 2012.
DOI : 10.1159/000225951

M. Cives and J. Strosberg, An update on gastroenteropancreatic neuroendocrine tumors, Oncol Williston Park N, vol.28, issue.9, pp.749-56, 2014.

O. Toole and D. , Current trend: endocrine tumors of the stomach, small bowel, colon and rectum], Gastroentérologie Clin Biol. Feb, vol.30, issue.2, pp.276-91, 2006.

G. Boutzios and G. Kaltsas, Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms, Front Horm Res, vol.44, pp.40-57, 2015.
DOI : 10.1159/000382053

P. Pellikka, A. Tajik, B. Khandheria, J. Seward, J. Callahan et al., Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients, Circulation, vol.87, issue.4, 1993.
DOI : 10.1161/01.CIR.87.4.1188

U. Pape, U. Berndt, J. Müller-nordhorn, M. Böhmig, S. Roll et al., Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours, Endocrine Related Cancer, vol.15, issue.4, pp.1083-97, 2008.
DOI : 10.1677/ERC-08-0017

C. Lombard-bohas, E. Mitry, O. Toole, D. Louvet, C. Pillon et al., Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France, Neuroendocrinology, vol.89, issue.2, pp.217-239, 2009.
DOI : 10.1159/000151562

M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg et al., ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, Neuroendocrinology, vol.378, issue.9808, pp.157-76, 2012.
DOI : 10.1016/S0140-6736(11)61742-X

E. Bertani, M. Falconi, C. Grana, E. Botteri, A. Chiappa et al., Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making, International Journal of Surgery, vol.20, pp.58-64
DOI : 10.1016/j.ijsu.2015.06.019

O. Farges, J. Maillochaud, and J. Belghiti, Traitement chirurgical des tumeurs endocrines digestives et pancréatiques. Hépato-Gastro Oncol Dig, pp.433-475, 2000.

G. Assignies, P. Fina, O. Bruno, M. Vullierme, F. Tubach et al., High Sensitivity of Diffusion-weighted MR Imaging for the Detection of Liver Metastases from Neuroendocrine Tumors: Comparison with T2-weighted and Dynamic Gadolinium-enhanced MR Imaging, Radiology, vol.268, issue.2, pp.390-399, 2013.
DOI : 10.1148/radiol.13121628

W. Meijer, E. Van-der-veer, P. Jager, E. Van-der-jagt, B. Piers et al., Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism, J Nucl Med Off Publ Soc Nucl Med. Feb, vol.44, issue.2, pp.184-91, 2003.

D. Kirkpatrick, E. Dawson, C. Haskell, and U. Batzdorf, Metastatic carcinoid presenting as a spinal tumor, Surg Neurol, vol.4, issue.3, pp.283-290, 1975.

K. Db, E. D. Cm, H. , and U. B. , Metastatic carcinoid presenting as a spinal tumor, Surg Neurol, vol.4, issue.3, pp.283-290, 1975.

A. Sabet, F. Khalaf, T. Haslerud, A. Zreiqat, A. Sabet et al., Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis, Am J Nucl Med Mol Imaging, vol.3, issue.5, pp.437-482, 2013.

H. Jann, S. Roll, A. Couvelard, O. Hentic, M. Pavel et al., Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome, Cancer, vol.14, issue.15, pp.3332-3373, 2011.
DOI : 10.1677/ERC-06-0074

J. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary et al., One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-72, 2008.
DOI : 10.1200/JCO.2007.15.4377

D. Dhall, R. Mertens, C. Bresee, R. Parakh, H. Wang et al., Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors, Human Pathology, vol.43, issue.4, pp.489-95
DOI : 10.1016/j.humpath.2011.06.011

T. Halfdanarson, K. Rabe, J. Rubin, and G. Petersen, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival, Annals of Oncology, vol.37, issue.8, pp.1727-1760, 2008.
DOI : 10.1016/S0959-8049(01)00073-9

URL : https://academic.oup.com/annonc/article-pdf/19/10/1727/659351/mdn351.pdf

A. Rinke, H. Müller, C. Schade-brittinger, K. Klose, P. Barth et al., Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, Journal of Clinical Oncology, vol.27, issue.28, pp.4656-63, 2009.
DOI : 10.1200/JCO.2009.22.8510

A. Ahmed, G. Turner, B. King, L. Jones, D. Culliford et al., Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study, Endocrine Related Cancer, vol.16, issue.3, pp.885-94, 2009.
DOI : 10.1677/ERC-09-0042

C. Durante, H. Boukheris, C. Dromain, P. Duvillard, S. Leboulleux et al., Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma, Endocrine Related Cancer, vol.16, issue.2, pp.585-97, 2009.
DOI : 10.1677/ERC-08-0301

URL : http://erc.endocrinology-journals.org/content/16/2/585.full.pdf

E. Janson, L. Holmberg, M. Stridsberg, B. Eriksson, E. Theodorsson et al., Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center, Annals of Oncology, vol.8, issue.7, pp.685-90, 1997.
DOI : 10.1023/A:1008215730767

A. Bernheim, H. Connolly, and P. Pellikka, Carcinoid heart disease, Current Treatment Options in Cardiovascular Medicine, vol.352, issue.Suppl2, pp.482-491, 2007.
DOI : 10.7326/0003-4819-120-4-199402150-00008

J. Strosberg, N. Gardner, and L. Kvols, Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut, Neuroendocrinology, vol.89, issue.4, pp.471-477, 2009.
DOI : 10.1159/000197899

F. Gibril, J. Doppman, J. Reynolds, C. Chen, V. Sutliff et al., Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management., Journal of Clinical Oncology, vol.16, issue.3, 1998.
DOI : 10.1200/JCO.1998.16.3.1040

K. Van-loon, L. Zhang, J. Keiser, C. Carrasco, K. Glass et al., Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect, 2015.

C. Korse, B. Taal, C. De-groot, R. Bakker, and J. Bonfrer, Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients With Neuroendocrine Tumor, Journal of Clinical Oncology, vol.27, issue.26, pp.4293-4302, 2009.
DOI : 10.1200/JCO.2008.18.7047

C. Korse, J. Bonfrer, N. Aaronson, A. Hart, and B. Taal, Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors, Neuroendocrinology, vol.89, issue.3, pp.296-301, 2009.
DOI : 10.1159/000162876

I. Kamaoui, V. De-luca, S. Ficarelli, N. Mennesson, C. Lombard-bohas et al., Value of CT Enteroclysis in Suspected Small-Bowel Carcinoid Tumors, American Journal of Roentgenology, vol.194, issue.3, 2010.
DOI : 10.2214/AJR.09.2760

F. Pilleul, M. Penigaud, L. Milot, J. Saurin, J. Chayvialle et al., Possible Small-Bowel Neoplasms: Contrast-enhanced and Water-enhanced Multidetector CT Enteroclysis, Radiology, vol.241, issue.3, pp.796-801, 2006.
DOI : 10.1148/radiol.2413051429

A. Becherer, M. Szabó, G. Karanikas, P. Wunderbaldinger, P. Angelberger et al., Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET, J Nucl Med Off Publ Soc Nucl Med, vol.45, issue.7, pp.1161-1168, 2004.

A. Chiti, S. Fanti, G. Savelli, A. Romeo, B. Bellanova et al., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.25, issue.10, pp.1396-403, 1998.
DOI : 10.1007/s002590050314

R. Lebtahi, G. Cadiot, N. Delahaye, R. Genin, D. Daou et al., Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy, J Nucl Med Off Publ Soc Nucl Med, vol.40, issue.10, pp.1602-1610, 1999.

S. Leboulleux, C. Dromain, A. Vataire, D. Malka, A. Aupérin et al., Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.3021-3029, 2008.
DOI : 10.1210/jc.2008-0459

E. Bombardieri, F. Giammarile, C. Aktolun, R. Baum, B. Delaloye et al., 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.65, issue.7, pp.2436-2482, 2010.
DOI : 10.1007/BF00173043

A. Jacobson, H. Deng, J. Lombard, H. Lessig, and R. Black, -Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.6, pp.2596-606, 2010.
DOI : 10.1210/jc.2009-2604

S. Ezziddin, T. Logvinski, C. Yong-hing, H. Ahmadzadehfar, H. Fischer et al., Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors, J Nucl Med Feb, vol.147, issue.2, pp.223-256, 2006.

G. Kaltsas, M. Korbonits, E. Heintz, J. Mukherjee, P. Jenkins et al., Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.2, 2001.
DOI : 10.1210/jcem.86.2.7194

J. Buscombe, J. Cwikla, M. Caplin, and A. Hilson, Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response, Nuclear Medicine Communications, vol.26, issue.11, pp.969-76, 2005.
DOI : 10.1097/01.mnm.0000184941.06123.b9

G. Kaltsas, M. Korbonits, E. Heintz, J. Mukherjee, P. Jenkins et al., Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.2, 2001.
DOI : 10.1210/jcem.86.2.7194

G. Kaltsas, A. Rockall, D. Papadogias, R. Reznek, and A. Grossman, Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours, European Journal of Endocrinology, vol.151, issue.1, pp.15-27, 2004.
DOI : 10.1530/eje.0.1510015

B. Taal, H. Zuetenhorst, V. Olmos, R. Hoefnagel, and C. , [131I]MIBG radionuclide therapy in carcinoid syndrome, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, vol.28, issue.3, p.243, 2002.

B. Taal, C. Hoefnagel, V. Olmos, R. Boot, H. Beijnen et al., Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors., Journal of Clinical Oncology, vol.14, issue.6, pp.1829-1867, 1996.
DOI : 10.1200/JCO.1996.14.6.1829

D. Kwekkeboom, W. De-herder, and E. Krenning, Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors, Endocrinology and Metabolism Clinics of North America, vol.40, issue.1, pp.173-85, 2011.
DOI : 10.1016/j.ecl.2010.12.003

C. Chougnet, S. Leboulleux, C. Caramella, J. Lumbroso, I. Borget et al., Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy, Endocrine Related Cancer, vol.286, issue.1-2, pp.229-268
DOI : 10.1016/j.mce.2007.12.002

J. Zuetenhorst, C. Hoefnageli, H. Boot, V. Olmos, R. Taal et al., Evaluation of (111)In- pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease, Nucl Med Commun, 2002.

W. Herder, . De, L. Hofland, A. Van-der-lely, and S. Lamberts, Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours, Endocrine Related Cancer, vol.10, issue.4, pp.451-459, 2003.
DOI : 10.1677/erc.0.0100451

A. Sundin, Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours, Best Practice & Research Clinical Gastroenterology, vol.26, issue.6, pp.803-821, 2012.
DOI : 10.1016/j.bpg.2012.12.004

E. Garin, L. Jeune, F. Devillers, A. Cuggia, M. De-lajarte-thirouard et al., Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors, Journal of Nuclear Medicine, vol.50, issue.6, pp.858-64, 2009.
DOI : 10.2967/jnumed.108.057505

D. Kwekkeboom, J. Teunissen, W. Bakker, P. Kooij, W. De-herder et al., ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors, Journal of Clinical Oncology, vol.23, issue.12, pp.2754-62, 2005.
DOI : 10.1200/JCO.2005.08.066

A. Sabet, F. Khalaf, T. Haslerud, A. Zreiqat, A. Sabet et al., Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis, Am J Nucl Med Mol Imaging, vol.3, issue.5, pp.437-482, 2013.

C. Johnbeck, U. Knigge, and A. Kjaer, PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature, Future Oncology, vol.54, issue.1, pp.2259-77, 2014.
DOI : 10.2967/jnumed.110.085142

N. Naswa, P. Sharma, A. Kumar, A. Nazar, R. Kumar et al., Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study, American Journal of Roentgenology, vol.197, issue.5, pp.1221-1229, 2011.
DOI : 10.2214/AJR.11.7298

A. Frilling, G. Sotiropoulos, A. Radtke, M. Malago, A. Bockisch et al., The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors, Annals of Surgery, vol.252, issue.5, 2010.
DOI : 10.1097/SLA.0b013e3181fd37e8

V. Froeling, F. Elgeti, M. Maurer, C. Scheurig-muenkler, A. Beck et al., Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia, Annals of Nuclear Medicine, vol.5, issue.9, pp.738-781, 2012.
DOI : 10.2174/1568009053202054

D. Wild, J. Bomanji, P. Benkert, H. Maecke, P. Ell et al., Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors, Journal of Nuclear Medicine, vol.54, issue.3, pp.364-72, 2013.
DOI : 10.2967/jnumed.112.111724

D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny et al., Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy, Journal of Nuclear Medicine, vol.50, issue.8, 2009.
DOI : 10.2967/jnumed.108.060236

V. Ambrosini, C. Nanni, M. Zompatori, D. Campana, P. Tomassetti et al., Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.68, 2010.

V. Ambrosini, P. Tomassetti, P. Castellucci, D. Campana, G. Montini et al., Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastroentero-pancreatic and lung neuro-endocrine tumours, Eur J Nucl Med Mol Imaging, 2008.

A. Haug, C. Auernhammer, B. Wängler, R. Tiling, G. Schmidt et al., Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.48, issue.5, pp.765-70, 2009.
DOI : 10.1007/s00259-008-1030-8

C. Soydal, Ga-68 Labeled Somatostatin Analogs Positron Emission Tomography/ Computed Tomography in Gastroenteropancreatic Neuroendocrine Tumors, Journal of Gastroenterology, Pancreatology & Liver Disorders, vol.1, issue.1, pp.1-4, 2014.
DOI : 10.15226/2374-815X/1/1/00105

S. Severi, O. Nanni, L. Bodei, M. Sansovini, A. Ianniello et al., Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.38, issue.3, pp.881-889
DOI : 10.1007/s00259-010-1610-2

T. Binderup, U. Knigge, A. Loft, J. Mortensen, A. Pfeifer et al., Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET, Journal of Nuclear Medicine, vol.51, issue.5, pp.704-716, 2010.
DOI : 10.2967/jnumed.109.069765

A. Sundin, Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours, Best Practice & Research Clinical Gastroenterology, vol.26, issue.6, pp.803-821, 2012.
DOI : 10.1016/j.bpg.2012.12.004

R. Abgral, S. Leboulleux, D. Deandreis, A. Auperin, J. Lumbroso et al., Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (???10%) Well-Differentiated Endocrine Carcinoma Staging, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.665-71, 2011.
DOI : 10.1210/jc.2010-2022

E. Blanchet, V. Martucci, and K. Pacak, Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging, Frontiers in Oncology, vol.1, p.58, 2012.
DOI : 10.3389/fonc.2011.00058

URL : https://doi.org/10.3389/fonc.2011.00058

K. Koopmans, E. De-vries, I. Kema, P. Elsinga, O. Neels et al., Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study, The Lancet Oncology, vol.7, issue.9, pp.728-762, 2006.
DOI : 10.1016/S1470-2045(06)70801-4

P. Jager, R. Chirakal, C. Marriott, A. Brouwers, K. Koopmans et al., 6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications, Journal of Nuclear Medicine, vol.49, issue.4, pp.573-86, 2008.
DOI : 10.2967/jnumed.107.045708

S. Balogova, J. Talbot, V. Nataf, L. Michaud, V. Huchet et al., 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type, European Journal of Nuclear Medicine and Molecular Imaging, vol.36, issue.8 Pt 1, pp.943-66, 2013.
DOI : 10.1097/MPA.0b013e318243a0b6

S. Kauhanen, M. Seppänen, J. Ovaska, H. Minn, J. Bergman et al., The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors, Endocrine Related Cancer, vol.16, issue.1, pp.255-65, 2009.
DOI : 10.1677/ERC-08-0229

F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. Beco et al., Can Fluorodihydroxyphenylalanine PET Replace Somatostatin Receptor Scintigraphy in Patients with Digestive Endocrine Tumors?, J Nucl Med, vol.47, issue.9, pp.1455-62, 2006.

K. Koopmans, O. Neels, I. Kema, P. Elsinga, W. Sluiter et al., C-5-Hydroxy-Tryptophan Positron Emission Tomography, Journal of Clinical Oncology, vol.26, issue.9, pp.1489-95, 2008.
DOI : 10.1200/JCO.2007.15.1126

H. Fehmann, U. Wulbrand, and R. Arnold, Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues. Recent Results Cancer Res Fortschritte Krebsforsch Prog Dans Rech Sur Cancer, pp.15-22, 2000.

G. Akerström, M. Falconi, R. Kianmanesh, P. Ruszniewski, and U. Plöckinger, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors, Mallorca Consensus Conference participants, pp.203-211, 2009.
DOI : 10.1159/000225949

D. Elias, A. David, I. Sourrouille, C. Honoré, D. Goéré et al., Neuroendocrine carcinomas: Optimal surgery of peritoneal metastases (and associated intra-abdominal metastases), Surgery, vol.155, issue.1, pp.5-12, 2014.
DOI : 10.1016/j.surg.2013.05.030

J. Boudreaux, B. Putty, D. Frey, E. Woltering, L. Anthony et al., Surgical Treatment of Advanced-Stage Carcinoid Tumors, Annals of Surgery, vol.241, issue.6, pp.839-884, 2005.
DOI : 10.1097/01.sla.0000164073.08093.5d

E. Woltering, P. Mamikunian, S. Zietz, S. Krutzik, V. Go et al., Effect of Octreotide LAR Dose and Weight on Octreotide Blood Levels in Patients With Neuroendocrine Tumors, Pancreas, vol.31, issue.4, pp.392-400, 2005.
DOI : 10.1097/01.mpa.0000186249.89081.0d

L. Hofland and S. Lamberts, The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance, Endocrine Reviews, vol.24, issue.1, pp.28-47, 2003.
DOI : 10.1210/er.2000-0001

A. Rinke, H. Müller, C. Schade-brittinger, K. Klose, P. Barth et al., Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, Journal of Clinical Oncology, vol.27, issue.28, pp.4656-63, 2009.
DOI : 10.1200/JCO.2009.22.8510

M. Caplin, M. Pavel, J. ?wik?a, A. Phan, M. Raderer et al., Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.371, issue.3, pp.224-257, 2014.
DOI : 10.1056/NEJMoa1316158

E. Wolin, K. Hu, G. Hughes, E. Bouillaud, V. Giannone et al., Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study, Cancer Chemotherapy and Pharmacology, vol.29, issue.Suppl 1, pp.387-95, 2013.
DOI : 10.1200/JCO.2010.33.2056

K. Detjen, M. Welzel, K. Farwig, F. Brembeck, A. Kaiser et al., Molecular mechanism of interferon alfa???Mediated growth inhibition in human neuroendocrine tumor cells, Gastroenterology, vol.118, issue.4, pp.735-783, 2000.
DOI : 10.1016/S0016-5085(00)70143-0

E. Janson and K. Oberg, Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon, Acta Oncologica, vol.30, issue.2, pp.225-234, 1993.
DOI : 10.1111/j.1365-2265.1989.tb00436.x

L. Kölby, G. Persson, S. Franzén, and B. Ahrén, Randomized clinical trial of the effect of interferon ?? on survival in patients with disseminated midgut carcinoid tumours, British Journal of Surgery, vol.11, issue.Suppl 1, pp.687-93, 2003.
DOI : 10.1023/A:1008314804492

R. Arnold, A. Rinke, K. Klose, H. Müller, M. Wied et al., Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial, Clinical Gastroenterology and Hepatology, vol.3, issue.8, pp.761-71, 2005.
DOI : 10.1016/S1542-3565(05)00481-7

S. Faiss, U. Pape, M. Böhmig, Y. Dörffel, U. Mansmann et al., Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors???The International Lanreotide and Interferon Alfa Study Group, Journal of Clinical Oncology, vol.21, issue.14, pp.2689-96, 2003.
DOI : 10.1200/JCO.2003.12.142

K. Yoshinaga, N. Oriuchi, H. Wakabayashi, Y. Tomiyama, M. Jinguji et al., Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry, Endocrine Journal, vol.61, issue.12, pp.611171-80, 2014.
DOI : 10.1507/endocrj.EJ14-0211

D. Bushnell, M. Madsen, T. O-'cdorisio, Y. Menda, S. Muzahir et al., Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res, p.38, 2014.

R. Valkema, S. Pauwels, L. Kvols, R. Barone, J. F. Bakker et al., Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors, Seminars in Nuclear Medicine, vol.36, issue.2, pp.147-56, 2006.
DOI : 10.1053/j.semnuclmed.2006.01.001

D. Bushnell, O. Dorisio, T. , O. Dorisio, M. Menda et al., Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide, Journal of Clinical Oncology, vol.28, issue.10, pp.1652-1661, 2010.
DOI : 10.1200/JCO.2009.22.8585

E. Bajetta, L. Ferrari, G. Procopio, L. Catena, E. Ferrario et al., Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours, Annals of Oncology, vol.13, issue.4
DOI : 10.1093/annonc/mdf064

M. Zappa, M. Abdel-rehim, O. Hentic, M. Vullierme, P. Ruszniewski et al., Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract, Targeted Oncology, vol.96, issue.5, pp.107-123
DOI : 10.1002/bjs.6587

R. Azoulay, M. Boudiaf, P. Soyer, L. Hamzi, M. Abitbol et al., Carcinoid tumor of the small bowel: value of hydro-MR imaging for diagnosis], J Radiol, vol.8412, issue.1, pp.1982-1987, 2003.

S. Leboulleux, C. Dromain, A. Vataire, D. Malka, A. Aupérin et al., Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.3021-3029, 2008.
DOI : 10.1210/jc.2008-0459

O. Toole and D. , Current trend: endocrine tumors of the stomach, small bowel, colon and rectum], Gastroentérologie Clin Biol. Feb, vol.30, issue.2, pp.276-91, 2006.

N. Zar, H. Garmo, L. Holmberg, J. Rastad, and P. Hellman, Long-term Survival of Patients with Small Intestinal Carcinoid Tumors, World Journal of Surgery, vol.7, issue.11, pp.1163-1171, 2004.
DOI : 10.1007/s00268-004-7610-2

J. Powell, Metastatic carcinoid of bone Report of two cases and review of the literature, Clin Orthop, pp.266-72, 1988.

M. Nocaudie-calzada, D. Huglo, B. Carnaille, C. Proye, and X. Marchandise, Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours, European Journal of Nuclear Medicine, vol.21, issue.11, pp.1448-54, 1996.
DOI : 10.1007/BF01254466

R. Lebtahi, G. Cadiot, N. Delahaye, R. Genin, D. Daou et al., Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy, J Nucl Med Off Publ Soc Nucl Med, vol.40, issue.10, pp.1602-1610, 1999.

A. Frilling, M. Malago, H. Martin, and C. Broelsch, Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors, Surgery, vol.124, issue.6, 1998.
DOI : 10.1067/msy.1998.93919

E. Ross and W. Roberts, The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease, The American Journal of Medicine, vol.79, issue.3, pp.339-54, 1985.
DOI : 10.1016/0002-9343(85)90313-4

M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute et al., 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT, Journal of Nuclear Medicine, vol.48, issue.4, pp.508-526, 2007.
DOI : 10.2967/jnumed.106.035667

URL : http://jnm.snmjournals.org/content/48/4/508.full.pdf

I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz et al., Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.2, pp.1617-1643, 2007.
DOI : 10.1148/radiology.166.1.3336704

A. Imperiale, E. Rust, S. Gabriel, J. Detour, B. Goichot et al., 18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation, Journal of Nuclear Medicine, vol.55, issue.3, pp.367-72, 2014.
DOI : 10.2967/jnumed.113.126896

F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J. Lotz et al., Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.4, pp.1295-301, 2009.
DOI : 10.1210/jc.2008-1349

F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. De-beco et al., Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?, J Nucl Med Off Publ Soc Nucl Med, 2006.

H. T. , Y. T. Suzuki-k, K. M. , and K. T. , Skeletal metastasis of carcinoid tumors: Two case reports and review of the literature, Oncol Lett, p.2012

F. Panzuto, S. Nasoni, M. Falconi, V. Corleto, G. Capurso et al., Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization, Endocrine Related Cancer, vol.12, issue.4, pp.1083-92, 2005.
DOI : 10.1677/erc.1.01017

URL : http://erc.endocrinology-journals.org/content/12/4/1083.full.pdf

J. Barton, B. Hirschowitz, P. Maton, and R. Jensen, Bone Metastases in Malignant Gastrinoma, Gastroenterology, vol.91, issue.5, pp.1179-85, 1986.
DOI : 10.1016/S0016-5085(86)80014-2

B. Kos-kud?a, O. Toole, D. Falconi, M. Gross, D. Klöppel et al., ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors, Neuroendocrinology, vol.91, issue.4, pp.341-50, 2010.
DOI : 10.1159/000287255

W. Meijer, E. Van-der-veer, P. Jager, E. Van-der-jagt, B. Piers et al., Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism, J Nucl Med Feb, vol.144, issue.2, pp.184-91, 2003.

S. Gupta, M. Johnson, R. Murthy, K. Ahrar, M. Wallace et al., Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors, Cancer, vol.17, issue.8, pp.1590-602, 2005.
DOI : 10.1016/S0016-5085(86)80014-2